Marshall Wace LLP Takes Position in Myomo, Inc. (NYSEAMERICAN:MYO)

Marshall Wace LLP purchased a new position in shares of Myomo, Inc. (NYSEAMERICAN:MYO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 88,780 shares of the company's stock, valued at approximately $572,000. Marshall Wace LLP owned about 0.29% of Myomo as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in MYO. Barclays PLC acquired a new stake in shares of Myomo in the 3rd quarter worth $36,000. Jane Street Group LLC purchased a new position in Myomo during the third quarter worth about $65,000. Walleye Capital LLC acquired a new stake in Myomo in the fourth quarter valued at about $66,000. Thompson Davis & CO. Inc. purchased a new stake in Myomo in the 4th quarter valued at approximately $181,000. Finally, Calamos Advisors LLC acquired a new position in Myomo during the 4th quarter worth approximately $189,000. Hedge funds and other institutional investors own 44.99% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on MYO. Alliance Global Partners reissued a "buy" rating on shares of Myomo in a report on Tuesday, March 11th. Craig Hallum boosted their target price on shares of Myomo from $9.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, March 11th. Ascendiant Capital Markets upped their price target on shares of Myomo from $9.00 to $11.00 and gave the stock a "buy" rating in a research note on Monday, March 17th. Finally, HC Wainwright raised their price objective on shares of Myomo from $7.50 to $9.50 and gave the company a "buy" rating in a research note on Wednesday, March 12th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $9.75.

Myomo Trading Up 3.0 %

Shares of MYO stock opened at $4.88 on Friday. The stock has a market capitalization of $147.62 million, a PE ratio of -21.22 and a beta of 1.68. Myomo, Inc. has a fifty-two week low of $2.76 and a fifty-two week high of $7.17. The firm has a fifty day moving average price of $4.85.

Insider Buying and Selling at Myomo

In related news, Director Thomas F. Kirk acquired 7,400 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was purchased at an average price of $5.00 per share, for a total transaction of $37,000.00. Following the transaction, the director now owns 255,933 shares in the company, valued at $1,279,665. This trade represents a 2.98 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Harry Kovelman sold 30,000 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $5.50, for a total transaction of $165,000.00. Following the completion of the transaction, the insider now owns 97,973 shares in the company, valued at approximately $538,851.50. This trade represents a 23.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.54% of the stock is currently owned by insiders.

About Myomo

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.

Want to see what other hedge funds are holding MYO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myomo, Inc. (NYSEAMERICAN:MYO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.